Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice

European Journal of Gynaecological Oncology

Volumn 26, Issue 4, 2005, Pages 398-402

  Kolberg, H C ^a   Villena Heinsen, C ^b   Deml, M M ^b   Kraemer, S ^c   Diedrich, K ^a   Friedrich, M ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c Krankenhaus Gerresheim   (Germany)

Author keywords

Chemotherapy; Nude mice; Ovarian cancer; p53; Proliferation markers

Indexed keywords

CISPLATIN; MONOCLONAL ANTIBODY KI 67; NAVELBINE; PACLITAXEL; PROTEIN ANTIBODY; PROTEIN P53; SODIUM CHLORIDE; TITANOCENE DICHLORIDE; TUMOR EXTRACT; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER TRANSPLANTATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CISPLATIN; FEMALE; GENES, P53; KI-67 ANTIGEN; MICE; MICE, NUDE; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; S PHASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 23744466832     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. World Health Organisation, International Agency for Research on Cancer European Commission: "Survival of cancer patients in Europe, the EUROCARE study". In: Berrino F., Sant M., Verdecchia A., Capocaccia R., Hakulinen T., Esteve J. (eds.) IARC Publication, 1995, No. 132, Lyon.
2. du Bois A., Richter B., Warm M. et al.: "Cisplatin/paclitaxel versus carboplatin/paclitaxel as 1st-line treatment in ovarian cancer" (abstract). Proc. Am. Soc. Clin. Oncol., 1998, 17, 361a.
3. du Bois A., Lück H.J., Meier W. et al.: "Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an AGO Study Group trial" (abstract). Proc. Am. Soc. Clin. Oncol., 1999, 18, 356a.
4. Sevelda P.: "Second-line therapy of ovarian carcinoma". Onkologie, 2000, 23, 593.
5. du Bois A., Lück H.J., Bauknecht T.: "2nd-line Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine sytematische Übersicht der publizierten Daten bis 1998". Geburtsh Frauenheilk, 2000, 60, 41.
6. Povlson C.O.: "Heterotransplants of human tumors in nude mice". Antibiot. Chemother., 1980, 28, 15.
7. Kleine W.: "Clinical prediction of experimental chemotherapy of gynaecological tumor xenografts". Behring Inst. Mitt., 1984, 74, 337.
8. Elkas J.C., Baldwin R.L., Pegram M., Tseng Y., Slamon D., Karlan B.Y.: "A human ovarian carcinoma murine xenograft model useful for preclinical trials". Gynecol. Oncol., 2002, 2, 200.
9. Moebius V.J., Stein R., Kieback D.G., Runnebaum I.B., Sass G., Kreienberg R.: "Antitumour activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivates". Anticancer Res., 1997, 17, 815.
10. Köpf-Maier P.: "Tumour inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract". Cancer Chemother. Pharmacol., 1989, 23, 225.
11. Kurbacher C.M., Nagel W., Mallmann P. et al.: "In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents". Anticancer Res., 1994, 14, 1529.
12. Harstrick A., Schmoll HJ., Sass G., Poliwoda H., Rustum Y: "Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines". Eur. J. Cancer, 1993, 29, 1000.
13. Köpf-Maier P.: "Complexes of metals other than platinum as anti-tumour agents". Eur. J. Clin. Pharmacol., 1994, 47, 1.
14. Kurbacher C.M., Bruckner H.W., Andreotti P.E., Kurbacher J.A., Sass G., Krebs D.: "In vitro activity of titanocenedichloride versus cisplatin in four ovarian cell lines evaluated by microtiter plate bioluminescence assay". Anticancer Drugs, 1995, 6, 697.
15. th Annual Meeting of the American Association for Cancer Research, 1995, 36, 391.
16. Melendez E.: "Titanium complexes in cancer treatment". Crit. Rev. Oncol. Hematol, 2002, 42, 309.
17. Mross K., Robben-Bathe P., Edler L., Baumgart J., Berdel W.E., Fiebig H., Unger C.: "Phase I clinical trial of a day-1, -3, -5 every 3 weeks schedule with titanocene dichloride (MKT 5) in patients with advanced cancer". Onkologie, 2000, 23, 576.
18. Christodoulou C.V., Ferry D.R., Fyfe D.W., Young A., Doran J., Sheehan TM. et al.: "Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer". J Clin. Oncol., 1998, 16, 2761.
19. Christodoulou C.V., Eliopoulos A.G., Young L.S., Hodgkins L., Ferry D.R., Kerr DJ.: "Anti-proliferative activity and mechanism of action in titanocene dichloride". Br. J. Cancer, 1998, 77, 2088.
20. Köpf-Maier R: "Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma". Anticancer Res., 1999, 19, 493.
21. Lummen G., Sperling H., Luboldt H., Otto T., Rubben H.: "Phase II trial of titanocene dichloride in advanced renal-cell carcinoma". Cancer Chemother. Pharmacol., 1998, 42, 415.
22. Hollstein M., Sidransky D., Vogelstein B., Harris C.C.: "p53 mutations in human cancers". Science, 1991, 253, 49.
23. Amundson S.A., Myers T.G., Fornace A.J.: "Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress". Oncogene, 1998, 17, 3287.
24. Shelling A.N., Cooke I.E., Ganesan T.S.: "The genetic analysis of ovarian cancer". Br. J. Cancer, 1995, 72, 521.
25. Röhlke P., Milde-Langosch K., Weyland C., Pichlmayer U., Jonat W., Löning T.: "p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with ki67 immunoreactivity". J. Cancer Res. Clin. Oncol., 1997, 123, 496.
26. Skirnisdottir I., Sorbe B., Karlsson M., Seidal T.: "Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma". Int. J. Oncol., 2001, 19, 1295.
27. Spacek J., Jilek P., Petera J., Tesarik Z.: "Histopathologic factors, serum markers and selected molecular biologic factors in ovarian carcinoma". Ceska Gynekol., 2002, 67, 343.
28. Frutuoso C., Silva M.R., Amaral N., Martins I., De Oliveira C., De Oliveira H.M.: "Prognosis value of p53, C-erB-2 and ki67 in ovarian carcinoma". Acta Med. Port., 2001, 14, 277.
29. Tachibana M., Watanabe J., Matsushima Y., Nishida K., Kobayashi Y., Fujimura M., Shiromizu K.: "Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma and related proteins". Int. J. Gynecol. Cancer, 2003, 13, 598.
30. Ikeda K., Sakai K., Yamamoto R., Hareyama H., Tsumura N., Watari H. et al.: "Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1 and p53 in stages II-IV in ovarian cancer". Int. J. Gynecol. Cancer, 2003, 13, 776.
31. Berker B., Dunder I., Ensari A., Cengiz S.D., Simsek E.: "Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma". Eur. J. Gynecol. Oncol., 2002, 23, 505.
32. Tomic S., Ilic Forko J., Babic D., Sundov D., Kuret S., Andelinovic S.: "c-erbB-2, p53 and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma". Croat. Med. J., 2003, 44, 429.
33. Havrilesky L., Darcy M., Hamdan H., Priore R.L., Leon J., Bell J., Berchuck A., Gynecologic Oncology Group Study: "Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study". J. Clin. Oncol., 2003, 21, 3814.
34. Berker B., Dunder I., Ensari A., Cengiz S.D.: "Prognostic value of p53 accumulation in epithelial ovarian carcinomas". Arch. Gynecol. Obstet., 2002, 266, 205.
35. Nakayama K., Takebayashi Y., Nakayama S., Hata K., Fujiwaki R., Fukumoto M., Miyazaki K.: "Prognostic value of overexpression of p53 in human ovarian cancer patients receiving cisplatin". Cancer Lett., 2003, 192, 227.
36. Gaducci A., Cosio S., Muraca S., Genazzani A.R.: "Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: Biological data and clinical implications". Eur. J. Gynecol. Oncol., 2002, 23, 390.
37. Goff B.A., Ries J.A., Els L.P., Coltrera M.D., Gown A.M.: "Immunophenotype of ovarian cancer as a predictor of clinical outcome: evaluation at primary surgery and second-look procedure". Gynecol. Oncol., 1998, 70, 378.
38. Henriksen R., Strang P., Backstrom T., Wilander E., Tribukait B., Oberg K.: "Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers". Anticancer Res., 1994, 14, 603.
39. Hüttner P.C., Weinberg D.S., Lage J.M.: "Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry". Am. J. Pathol., 1992, 141, 699.
40. Thompson A.M., Anderson T.J., Condie A., Prosser J., Chetty U., Carter D.C. et al.: "p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters". Int. J. Cancer, 1992, 50, 528.
41. Mink D.: "Zusammenhänge zwischen der Expression von Steroid-hormonrezeptoren und der proliferativen Aktivität beim Mammakarzinom". Habilitationsschrift, Medizinische Fakultät der Universität des Saarlandes, 1995, Homburg/Saar.
42. Garzetti G.G., Ciavattini A., Goteri G., de Nictolis M., Stramazotti j D., Lucarini G., Biagini G.: "Ki67 antigen immunostaining (MIB 1 Monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance". Gynecol. Oncol., 1995, 56, 169.
43. Kolfschoten G.M., Hulscher T.M., Pinedo H.M., Boven E.: "Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts". Br. J. Cancer, 2000, 83, 921.
44. Kimmig R., Wimberger P., Hillemanns P., Kapsner T., Caspari C., Hepp H.: "Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labelled tumor cells". Gynecol. Oncol., 2002, 84, 21.
45. Vindelov L.L., Christensen I.J., Nissen N.I.: "A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis". Cytometry, 1983, 3, 323.
46. Azar H.A., Fernandez S.B., Bros L.M., Sullivan J.L.: "Human tumour xenografts in athymic nude mice: chemotherapy trials in serially transplanted tumours". Ann. Clin. Lab. Sci., 1982, 12, 51.
47. Kyriazis A.A., Kyriazis A.P., Kereiakes J.G., Soloway M.S., McCombs W.B.: "Histopathologic evaluation of response to treatment of human tumours grown in the nude mice". Exp. Cell. Biol., 1983, 51, 83.
48. Shorthouse A.J., Smyth J.F., Steel G.G., Ellison M., Mills J., Peckham M.J.: "The human tumour xenograft a valid model in experimental chemotherapy". Brit. J. Surg., 1980, 67, 715.
49. Steel G.G., Courtenay V.D., Peckham M.J.: "The response to chemotherapy of a variety of human tumour xenografts". Cancer, 1983, 47, 1.
50. Friedrich M., Villena-Heinsen C., Farnhammer C., Schmidt W.: "Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice". Eur. J. Gynaecol. Oncol., 1998, 19, 333.
51. Villena-Heinsen C., Friedrich M., Ertan A.K., Schmidt W.: "Human tumour xenografts in nude mice: chemotherapy trials with titanocene dichloride in different dosages". Clin. Exp. Obstet. Gynecol., 1998, 25, 5.
52. Villena-Heinsen C., Friedrich M., Ertan A.K., Farnhammer C., Schmidt W.: "Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride". Anticancer Drugs, 1998, 9, 557.